An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
ChEBI ID: 35941
| Member | Definition | Class |
|---|---|---|
| 1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride | A hydrochloride salt that is obtained by reaction of 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide with one equivalent of hydrogen chloride. Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo. | 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide hydrochloride |
| 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine | A N-arylpiperazine that is piperazine substituted by 2-(4-aminophenyl)ethyl and 3-(trifluoromethyl)phenyl groups at positions 1 and 4, respectively. It is a selective 5-HT1A serotonin receptor agonist and 5-HT1D serotonin receptor antagonist. | LY-165163 |
| 1-(3-chlorophenyl)piperazine | A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone. | 1-(3-chlorophenyl)piperazine |
| 1-(3-trifluoromethylphenyl)piperazine | A N-arylpiperazine that is piperazine substituted by a 3-(trifluoromethyl)phenyl group at position 1. A serotonergic agonist used as a recreational drug. | 1-(3-(trifluoromethyl)phenyl)piperazine |
| 1-benzylpiperazine | A tertiary amino compound that is piperazine substituted by a benzyl group at position 1. It is a serotonergic agonist used as a recreational drug. | 1-benzylpiperazine |
| 2-methyl-5-ht | 2-methylserotonin | |
| 5-(nonyloxy)tryptamine | A tryptamine derivative that consists of serotonin bearing an additional O-nonyl substituent. 5-HT1B selective agonist, several times more potent than sumatriptan and inactive as a 5-HT1A agonist (Ki at 5-HT1B = 1 nM, selectivity over 5-HT1A > 300-fold). | 5-nonyloxytryptamine |
| 5-methoxytryptamine | A member of the class of tryptamines that is the methyl ether derivative of serotonin. | 5-methoxytryptamine |
| almotriptan | An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position. | almotriptan |
| alpha-methylserotonin | alpha-methylserotonin | |
| aripiprazole | An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. | aripiprazole |
| aripiprazole lauroxil | A dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. | aripiprazole lauroxil |
| buspirone | An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position. | buspirone |
| buspirone hydrochloride | A hydrochloride salt resulting from the reaction of equimolar amounts of buspirone and hydrogen chloride. | buspirone hydrochloride |
| cgs 12066 | A pyrroloquinoxaline that is pyrrolo[1,2-a]quinoxaline bearing additional 4-methylpiperazin-1-yl and trifluoromethyl substituents at positions 4 and 7 respectively. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration. | 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline |
| cgs 12066b | A maleate salt that is the dimaleate salt of 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration. | 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate |
| dexfenfluramine | The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects. | (S)-fenfluramine |
| dexfenfluramine hydrochloride | The hydrochloride salt of (S)-fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike the racemate it does not possess catecholamine agonist activity. It was formerly given by mouth in the treatment of obesity, but, like the racemate, was withdrawn wolrdwide following reports of valvular heart defects. | (S)-fenfluramine hydrochloride |
| dihydroergotamine | Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension. | dihydroergotamine |
| dihydroergotamine mesylate | The methanesulfonic acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the mesylate and the tartrate salts are used for the treatment of migraine and orthostatic hypotension. | dihydroergotamine mesylate |
| eletriptan | An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group. | eletriptan |
| ergotamine | A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. | ergotamine |
| fenfluramine | A secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension. | fenfluramine |
| flibanserin | An N-alkylpiperazine that is 1-[2-(1,3-dihydro-2-oxobenzimidazol-1-yl)ethyl]piperazine in which the remaining amino proton is replaced by a 3-(trifluoromethyl)phenyl group. A multifunctional serotonin agonist and antagonist which is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder. | flibanserin |
| lisuride | lisuride | |
| lysergic acid diethylamide | An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine. | lysergic acid diethylamide |
| n-methylquipazine | An aminoquinoline that consists of quinoline in which the hydrogen at position 2 is substituted by a 4-methylpiperazin-1-yl group. A 5-HT3 agonist. Has almost the same affinity for 5-HT3 sites as quipazine but unlike the latter, does not bind to 5-HT1B sites. | N-methylquipazine |
| naratriptan | naratriptan | |
| psilocin | A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms"). | psilocin |
| psilocybin | A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms"). | psilocybin |
| rizatriptan | rizatriptan | |
| sumatriptan | A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults. | sumatriptan |
| tegaserod | tegaserod | |
| tegaserod maleate | tegaserod maleate | |
| tetrindole | A racemate composed of equimolar amounts of (R)- and (S)-tetrindole hydrochloride. | tetrindole hydrochloride |
| vilazodone | A 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder. | vilazodone |
| vilazodone hydrochloride | A hydrochloride obtained by reaction of vilazodone with one equivalent of hydrochloric acid. Used for the treatment of major depressive disorder. | vilazodone hydrochloride |
| vortioxetine | An N-arylpiperazine in which the aryl group is specified as 2-[(2,4-dimethylphenyl)sulfanyl]phenyl. Used (as its hydrobromide salt) for treatment of major depressive disorder. | vortioxetine |
| xaliproden | A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine which is substituted on the nitrogen by a 2-(2-naphthyl)ethyl group and at position 4 by a m-trifluoromethylphenyl group. | xaliproden |
| xanomeline | xanomeline | |
| zolmitriptan | A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine. | zolmitriptan |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 8,611 (37.49) | 18.7374 |
| 1990's | 4,573 (19.91) | 18.2507 |
| 2000's | 4,263 (18.56) | 29.6817 |
| 2010's | 3,950 (17.20) | 24.3611 |
| 2020's | 1,570 (6.84) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 3,272 (12.10%) | 5.53% |
| Reviews | 3,066 (11.34%) | 6.00% |
| Case Studies | 2,269 (8.39%) | 4.05% |
| Observational | 65 (0.24%) | 0.25% |
| Other | 18,363 (67.92%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 67.9K protein | Vaccinia virus | Potency | 14.4332 | 2 | 4 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 36.9713 | 3 | 16 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 26.8325 | 2 | 2 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 16.4087 | 1 | 8 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 22.9284 | 7 | 18 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 21.3997 | 2 | 3 |
| arylsulfatase A | Homo sapiens (human) | Potency | 6.7178 | 1 | 3 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 36.6108 | 1 | 1 |
| Ataxin-2 | Homo sapiens (human) | Potency | 14.8344 | 2 | 5 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 3.3801 | 1 | 3 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 10.8497 | 1 | 3 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 2 | 2 |
| BRCA1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.7946 | 1 | 1 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 22.6874 | 1 | 2 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 22.6874 | 1 | 2 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 25.5347 | 2 | 5 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 22.1060 | 2 | 4 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.3824 | 1 | 4 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 44.6684 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 25.1189 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 51.6475 | 1 | 4 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 10.7040 | 1 | 5 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 11.1936 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 30.7828 | 1 | 5 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 70.3008 | 2 | 9 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 12.7190 | 1 | 5 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 24.5367 | 1 | 5 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 29.8852 | 1 | 6 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 7.9128 | 1 | 13 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 21.4792 | 1 | 9 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 16.7428 | 2 | 14 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 25.7742 | 1 | 9 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 5.3929 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 5.1423 | 2 | 9 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 64.4679 | 1 | 2 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 56.9322 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 6.8327 | 1 | 3 |
| endonuclease IV | Escherichia coli | Potency | 0.2818 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 29.8972 | 9 | 30 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 29.3477 | 3 | 6 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 27.5977 | 9 | 29 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 24.3274 | 1 | 12 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 5.6987 | 4 | 10 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 30.3899 | 3 | 6 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 36.9850 | 1 | 4 |
| G | Vesicular stomatitis virus | Potency | 29.8852 | 1 | 6 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| GALC protein | Homo sapiens (human) | Potency | 4.4668 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 16.7428 | 1 | 7 |
| geminin | Homo sapiens (human) | Potency | 14.8311 | 2 | 8 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 22.7551 | 2 | 14 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.6988 | 2 | 3 |
| GLS protein | Homo sapiens (human) | Potency | 15.4903 | 2 | 7 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 14.7830 | 1 | 6 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 4.4668 | 1 | 2 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 37.9113 | 1 | 4 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 40.6685 | 2 | 6 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 4.4668 | 1 | 2 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 21.2455 | 2 | 23 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 22.3938 | 1 | 4 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 76.1722 | 2 | 5 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 29.8852 | 1 | 6 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 25.1738 | 2 | 6 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 12.5893 | 2 | 2 |
| IDH1 | Homo sapiens (human) | Potency | 3.2860 | 1 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 29.8852 | 1 | 12 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Interferon beta | Homo sapiens (human) | Potency | 22.1487 | 3 | 16 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 12.2097 | 1 | 2 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 13.8154 | 1 | 2 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 1.7783 | 2 | 2 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 13.8282 | 2 | 7 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8904 | 1 | 3 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 17.6528 | 2 | 8 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 1.7783 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 5.3373 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 0.3162 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 27.0458 | 2 | 9 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.5195 | 1 | 3 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 34.9121 | 2 | 4 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 14.3390 | 2 | 3 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 25.3262 | 3 | 11 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 26.7518 | 1 | 4 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 80.3039 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 30.9479 | 2 | 6 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 19.9141 | 3 | 7 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 40.8604 | 1 | 5 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.4125 | 1 | 1 |
| polyprotein | Zika virus | Potency | 36.9850 | 1 | 4 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 15.0744 | 1 | 4 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 13.4813 | 1 | 9 |
| PPM1D protein | Homo sapiens (human) | Potency | 17.1178 | 1 | 6 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 24.5877 | 2 | 11 |
| progesterone receptor | Homo sapiens (human) | Potency | 19.1021 | 2 | 7 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 28.4830 | 2 | 6 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 17.0960 | 1 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 43.6162 | 3 | 9 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 30.1933 | 2 | 9 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 18.4927 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 22.9875 | 3 | 6 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 22.9875 | 3 | 6 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 31.5392 | 2 | 8 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 28.1838 | 1 | 2 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 22.1982 | 2 | 33 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 4.2284 | 2 | 2 |
| Thrombopoietin | Homo sapiens (human) | Potency | 9.6704 | 2 | 6 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 40.2009 | 2 | 15 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 18.5482 | 2 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 38.1153 | 6 | 15 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 5.7457 | 1 | 2 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.4125 | 1 | 1 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.4125 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 32.9616 | 1 | 4 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 22.3319 | 2 | 11 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 42.6414 | 3 | 7 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 57.4570 | 1 | 2 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 37.9113 | 1 | 4 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | Ki | 0.0220 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.1752 | 10 | 10 |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | IC50 | 0.4500 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.3882 | 9 | 17 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.0629 | 63 | 75 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.1962 | 23 | 40 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | IC50 | 0.0154 | 7 | 9 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 2.6522 | 8 | 14 |
| 5-hydroxytryptamine receptor 1B | Gorilla gorilla gorilla (western lowland gorilla) | Ki | 0.0064 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 0.0239 | 15 | 22 |
| 5-hydroxytryptamine receptor 1B | Oryctolagus cuniculus (rabbit) | Ki | 0.0012 | 1 | 1 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.2389 | 10 | 21 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | IC50 | 0.2470 | 10 | 13 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 1.6870 | 3 | 3 |
| 5-hydroxytryptamine receptor 1D | Sus scrofa (pig) | IC50 | 0.0593 | 6 | 6 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 0.0556 | 22 | 30 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.0167 | 3 | 4 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | IC50 | 5.5000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1E | Homo sapiens (human) | Ki | 6.6977 | 2 | 3 |
| 5-hydroxytryptamine receptor 1F | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Homo sapiens (human) | Ki | 0.0257 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.0167 | 3 | 4 |
| 5-hydroxytryptamine receptor 2A | Bos taurus (cattle) | IC50 | 18.6209 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 3.2088 | 7 | 10 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 4.0190 | 9 | 10 |
| 5-hydroxytryptamine receptor 2A | Bos taurus (cattle) | Ki | 0.1780 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.1630 | 42 | 47 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.9264 | 27 | 32 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.1533 | 2 | 5 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 2.0617 | 5 | 6 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.0421 | 13 | 16 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 1.5544 | 15 | 18 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 15.3628 | 13 | 16 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 1.9212 | 7 | 8 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.1388 | 20 | 24 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 1.3555 | 25 | 30 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | IC50 | 630.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | IC50 | 3.4838 | 7 | 9 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 2.5946 | 4 | 4 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 2.0867 | 8 | 13 |
| 5-hydroxytryptamine receptor 3A | Mus musculus (house mouse) | Ki | 1.4300 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | Ki | 0.5803 | 6 | 8 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | IC50 | 3.0493 | 5 | 7 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 2.5946 | 4 | 4 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.4873 | 2 | 7 |
| 5-hydroxytryptamine receptor 3B | Mus musculus (house mouse) | Ki | 1.4300 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | Ki | 0.5803 | 6 | 8 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | IC50 | 3.0493 | 5 | 7 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.4873 | 2 | 7 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | IC50 | 3.0493 | 5 | 7 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.4873 | 2 | 7 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | IC50 | 3.0493 | 5 | 7 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.4873 | 2 | 7 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.0553 | 1 | 3 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 2.5215 | 2 | 4 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | Ki | 0.0456 | 7 | 7 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 0.2520 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | IC50 | 0.5012 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 1.2658 | 6 | 8 |
| 5-hydroxytryptamine receptor 5A | Mus musculus (house mouse) | Ki | 9.1333 | 2 | 3 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 0.0057 | 1 | 3 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 3.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.3316 | 15 | 19 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.3163 | 21 | 25 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 3.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.0908 | 4 | 5 |
| Acetylcholinesterase | Mus musculus (house mouse) | IC50 | 21.3000 | 1 | 1 |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | IC50 | 21.3000 | 2 | 2 |
| Adenylate cyclase | Arthrospira platensis | IC50 | 70.0000 | 1 | 1 |
| Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | IC50 | 0.0468 | 1 | 1 |
| Advanced glycosylation end product-specific receptor | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 4.6414 | 6 | 7 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 6.3111 | 4 | 9 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0306 | 3 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.1711 | 6 | 8 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | IC50 | 1.9800 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 6.3111 | 4 | 9 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.2100 | 2 | 3 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.1924 | 5 | 7 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.6352 | 2 | 5 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 6.3111 | 4 | 9 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.1288 | 2 | 5 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.1924 | 5 | 7 |
| Alpha-2A adrenergic receptor | Bos taurus (cattle) | IC50 | 0.0223 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 1.5009 | 2 | 4 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 2 | 4 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.0004 | 1 | 3 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 5.0119 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 1.5021 | 2 | 4 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 2 | 4 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.0013 | 1 | 3 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 5.0119 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 1.5066 | 2 | 4 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 7.7500 | 2 | 4 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0105 | 2 | 4 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 5.0119 | 1 | 1 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 | 0.0240 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 5 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 0.7800 | 1 | 1 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 308.2725 | 2 | 4 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | Ki | 551.7000 | 2 | 4 |
| bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 | 20.0000 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 2.2337 | 2 | 3 |
| Beta-1 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.9517 | 2 | 3 |
| Beta-2 adrenergic receptor | Canis lupus familiaris (dog) | IC50 | 18.0000 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | IC50 | 1.4010 | 1 | 2 |
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 0.8890 | 2 | 3 |
| Beta-3 adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 118.1230 | 5 | 10 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 369.8000 | 1 | 1 |
| C-C chemokine receptor type 6 | Homo sapiens (human) | IC50 | 23.4000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 5 |
| Carboxypeptidase M | Homo sapiens (human) | IC50 | 0.0200 | 1 | 1 |
| Caspase-3 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Catechol O-methyltransferase | Rattus norvegicus (Norway rat) | Ki | 0.0025 | 1 | 1 |
| Cholecystokinin receptor type A | Homo sapiens (human) | Ki | 0.3020 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 0.0160 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 7.5748 | 3 | 4 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.5740 | 1 | 2 |
| D | Bos taurus (cattle) | IC50 | 270.0000 | 1 | 2 |
| D | Rattus norvegicus (Norway rat) | IC50 | 0.1200 | 1 | 2 |
| D | Mus musculus (house mouse) | Ki | 0.5900 | 2 | 2 |
| D | Rattus norvegicus (Norway rat) | Ki | 0.9902 | 4 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 1.4320 | 1 | 3 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.5305 | 7 | 11 |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1200 | 1 | 2 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 1.1800 | 3 | 3 |
| D(2) dopamine receptor | Bos taurus (cattle) | IC50 | 4.0000 | 2 | 3 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.0465 | 5 | 9 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.2713 | 6 | 7 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.2481 | 49 | 54 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.3348 | 9 | 9 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.0135 | 1 | 4 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 0.1037 | 2 | 3 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.0057 | 23 | 27 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | IC50 | 1.2133 | 2 | 3 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.1498 | 12 | 13 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.5100 | 1 | 1 |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | Ki | 0.0269 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 0.0032 | 1 | 2 |
| Gastrin/cholecystokinin type B receptor | Homo sapiens (human) | Ki | 0.3020 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.3550 | 4 | 4 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0489 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.2865 | 6 | 6 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.0400 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.0220 | 1 | 1 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 1.3855 | 2 | 2 |
| Histamine H4 receptor | Homo sapiens (human) | Ki | 6.9183 | 1 | 1 |
| LacZ protein (plasmid) | Escherichia coli | IC50 | 66.6000 | 1 | 1 |
| Lysosomal alpha-glucosidase | Bos taurus (cattle) | IC50 | 0.0300 | 1 | 1 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 | 0.0003 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 35.3000 | 1 | 4 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 186.2000 | 1 | 3 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 5 |
| Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.1585 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 1.3967 | 6 | 6 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 0.6829 | 10 | 10 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | Ki | 0.1585 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.1644 | 2 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.5456 | 13 | 13 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.0449 | 4 | 4 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.0251 | 2 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.0407 | 4 | 4 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.7082 | 8 | 8 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 2.9194 | 8 | 9 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 0.8793 | 3 | 3 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 107.3600 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 107.3600 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.3165 | 3 | 5 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.9520 | 2 | 3 |
| Sodium-dependent dopamine transporter | Macaca fascicularis (crab-eating macaque) | Ki | 0.3400 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0250 | 1 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 0.2950 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.3400 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.1581 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.0004 | 3 | 3 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | IC50 | 0.0054 | 5 | 6 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.4050 | 9 | 9 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 100.3000 | 1 | 3 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 3.0640 | 1 | 1 |
| Transient receptor potential cation channel subfamily M member 8 | Homo sapiens (human) | IC50 | 12.0000 | 2 | 2 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 3.1600 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 6.4990 | 1 | 1 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 | 10.3500 | 2 | 2 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | EC50 | 0.1266 | 16 | 16 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | EC50 | 1.3000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Kd | 0.1275 | 1 | 4 |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | EC50 | 6.0285 | 3 | 5 |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | EC50 | 0.0095 | 7 | 10 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | EC50 | 0.0970 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Homo sapiens (human) | EC50 | 0.0350 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | EC50 | 0.2857 | 23 | 25 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | EC50 | 2.8042 | 2 | 3 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | EC50 | 0.5123 | 4 | 5 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | EC50 | 0.3021 | 10 | 11 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | EC50 | 0.0789 | 12 | 13 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | EC50 | 0.0018 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | EC50 | 0.0094 | 2 | 2 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | EC50 | 0.0048 | 5 | 5 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0800 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0800 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.0800 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Kd | 0.0282 | 1 | 1 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.2089 | 1 | 1 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.3780 | 1 | 2 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0234 | 2 | 3 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.3780 | 1 | 2 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0234 | 2 | 3 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | EC50 | 0.3780 | 1 | 2 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Kd | 0.0234 | 2 | 3 |
| Caspase-3 | Homo sapiens (human) | EC50 | 50.0000 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | EC50 | 0.7938 | 24 | 29 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Kd | 0.0008 | 4 | 5 |
| D(3) dopamine receptor | Homo sapiens (human) | EC50 | 0.0198 | 2 | 4 |
| D(4) dopamine receptor | Homo sapiens (human) | EC50 | 0.0885 | 1 | 1 |
| mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 | 92.4690 | 1 | 1 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | EC50 | 1.7005 | 16 | 16 |
| Muscarinic acetylcholine receptor M1 | Mus musculus (house mouse) | EC50 | 5.7000 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | EC50 | 0.2595 | 2 | 2 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | EC50 | 13,270,233,341.7463 | 3 | 3 |
| Muscarinic acetylcholine receptor M3 | Mus musculus (house mouse) | EC50 | 11.0000 | 1 | 1 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | EC50 | 0.9673 | 7 | 7 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | EC50 | 3.2343 | 7 | 7 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | EC50 | 0.1080 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | EC50 | 0.0005 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | EC50 | 0.0120 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | EC50 | 0.0120 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | EC50 | 0.0120 | 1 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | EC50 | 0.0120 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | ED50 | 0.1925 | 1 | 2 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Efficacy | 0.0515 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | K0.5 | 0.0060 | 1 | 1 |
| DNA repair protein RAD52 homolog isoform a | Homo sapiens (human) | AC50 | 16.7200 | 1 | 1 |
| PAX8 | Homo sapiens (human) | AC50 | 12.4100 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Km | 55.0000 | 1 | 1 |